Clinical Trials
4 trialsNCT03532451 2024-09-19
PrE0807
PrECOG, LLC.
Phase 1 Completed
NCT03203876 2022-03-10
A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT02252263 2017-11-01
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
Bristol-Myers Squibb
Phase 1 Completed
NCT01750580 2015-07-22
Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor
Bristol-Myers Squibb
Phase 1 Completed